
==== Front
Can J Respir Ther
Can J Respir Ther
3251
Canadian Journal of Respiratory Therapy: CJRT = Revue Canadienne de la Thérapie Respiratoire : RCTR
1205-9838
2368-6820
Canadian Society of Respiratory Therapists Website: Canadian Journal of Respiratory Therapy

38855380
118514
10.29390/001c.118514
Research Article
Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study
Pina Belmonte Adela 1
Madrazo Manuel 1
Piles Laura 1
Rubio-Rivas Manuel 2
de Jorge Huerta Lucía 3
Gómez Antúnez María 4
López Caleya Juan Francisco 5
Arnalich Fernández Francisco 6
Gericó-Aseguinolaza Martin 7
Pesqueira Fontan Paula Maria 8
Rhyman Nicolás 9
Prieto Dehesa Marina 10
Romero Cabrera Juan Luis 11
García García Gema María 12
García-Casasola Gonzalo 13
Labirua-Iturburu Ruiz Ane 14
Carrasco-Sánchez Francisco Javier 15
Martínez Hernández Sara 16
Pascual Pérez Maria de los Reyes 17
López Castro José 18
Serrano Carrillo de Albornoz José Luis 19
Varona José F. 20
Gómez-Huelgas Ricardo 21
Antón-Santos Juan-Miguel 13
Lumbreras-Bermejo Carlos 3
1 Medicina Interna Hospital Universitario Doctor Peset https://ror.org/03971n288
2 Medicina Interna Bellvitge University Hospital https://ror.org/00epner96
3 Medicina Interna Hospital Universitario 12 De Octubre https://ror.org/00qyh5r35
4 Medicina Interna Hospital General Universitario Gregorio Marañón https://ror.org/0111es613
5 Medicina Interna Hospital de Cabueñes https://ror.org/03yw66316
6 Medicina Interna Hospital Universitario La Paz https://ror.org/01s1q0w69
7 Medicina Interna Hospital Royo Villanova https://ror.org/01aqax545
8 Medicina Interna Hospital Clinico de Santiago de Compostela
9 Medicina Interna Hospital de Sant Joan Despí Moisès Broggi https://ror.org/03n6b6g81
10 Medicina Interna Hospital Universitario Río Hortega https://ror.org/05jk45963
11 Medicina Interna Hospital Universitario Reina Sofía https://ror.org/02vtd2q19
12 Medicina Interna Hospital Universitario de Badajoz
13 Medicina Interna Hospital Universitario Infanta Cristina https://ror.org/05txkk980
14 Medicina Interna Hospital Santa Marina
15 Medicina Interna Hospital Juan Ramón Jiménez https://ror.org/03fpqn433
16 Medicina Interna Hospital San Pedro https://ror.org/031va0421
17 Medicina Interna Hospital General Universitario de Elda
18 Medicina Interna Hospital Público de Monforte de Lemos
19 Medicina Internas Hospital de Poniente https://ror.org/017a18y80
20 Medicina Interna Hospital Universitario Montepríncipe
21 Medicina Interna Biomedical Research Institute of Málaga (IBIMA)
Corresponding author: pina.adela@gmail.com
5 6 2024
2024
60 Vol. 60, Issue 1, 2024 8694
3 11 2023
23 5 2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (4.0) which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Background

Patients with chronic lung disease (CLD), such as asthma or chronic obstructive pulmonary disease, were expected to have an increased risk of clinical manifestations and severity of COVID-19. However, these comorbidities have been reported less frequently than expected. Chronic treatment with inhaled corticosteroids (ICS) may impact the clinical course of COVID-19. The main objective of this study is to know the influence of chronic treatment with ICS on the prognosis of COVID-19 hospitalized patients with CLD.

Methods

A multicenter retrospective cohort study was designed, including patients hospitalized with COVID-19. Epidemiological and clinical data were collected at admission and at seven days, and clinical outcomes were collected. Patients with CLD with and without chronic treatment with ICS were compared.

Results

Two thousand five hundred ninety-eight patients were included, of which 1,171 patients had a diagnosis of asthma and 1,427 of COPD (53.37% and 41.41% with ICS, respectively). No differences were found in mortality, transfer to ICU, or development of moderate-severe ARDS. Patients with chronic ICS had a longer hospital stay in both asthma and COPD patients (9 vs. 8 days, p = 0.031 in asthma patients), (11 vs. 9 days, p = 0.018 in COPD patients); although they also had more comorbidity burden.

Conclusions

Patients with chronic inhaled corticosteroids had longer hospital stays and more chronic comorbidities, measured by the Charlson comorbidity index, but they did not have more severe disease at admission, evaluated with qSOFA and PSI scores. Chronic treatment with inhaled corticosteroids had no influence on the prognosis of patients with chronic lung disease and COVID-19.

inhaled corticosteroids
COVID-19
prognosis
mortality
inflammation
lung disease
This research has not received specific support from public sector agencies, the commercial sector or non-profit entities.
==== Body
pmcIntroduction

SARS-CoV-2 develops a respiratory disease with systemic involvement.1 Severity of the disease is variable; in a Chinese study with 72314 cases2 including outpatients and patients admitted to hospital, 14% had severe pneumonia, and 5% were critical cases. Also, another Chinese study1 reported that 15-20% of the inpatients required ventilatory support. Overall mortality has been reported from 21 to 28% in hospitalized patients,3,4 and it rises to 61.5 to 62% in patients in an Intensive Care Unit (ICU)4,5

Patients with chronic lung diseases (CLD), particularly chronic obstructive pulmonary disease (COPD) and asthma, would be expected to be at increased risk of SARS-COV-2 infection and more severe COVID-19 course.6–12 However, none of these diseases are main comorbidities in patients with COVID-19.6,13 Only 0.95% - 5.1% of admitted patients with COVID-19 had a CLD.14,15 A study reported a lower risk of hospital admission for COVID-19 in patients with COPD and asthma.16

It has been hypothesized that chronic inhaled corticosteroids (ICS) could affect the development of SARS-COV-2 infection.6,15 In patients with COPD and asthma, ICS has been associated with an increased risk of upper respiratory infections, and ICS has been associated with a higher prevalence of pneumonia.17 Furthermore, in-vitro models suggest that ICS could delay virus clearance.17 In contrast, ICS alone or in combination with bronchodilators has been shown to suppress coronavirus replication and cytokine production in HCoV-229 coronavirus infection in in-vitro models.18 Moreover, ciclesonide suppresses viral replication of SARS-COV-2 in-vitro, ICS downregulates the SARS-COV-2 receptor ACE2 in-vitro in COPD patients, and long-term use of inhaled corticosteroids for controlling asthma is likely to have a beneficial modulatory effect on COVID-19.19–21

Taking into account the contradictory data on the possible benefits6,14–16,18–21 or harms6,17 of inhaled corticosteroids (which are administered worldwide to the majority of asthmatic and COPD patients16) on the prognosis of COVID-19, we have carried out this study to investigate the influence that chronic ICS may have on the prognosis of COVID-19 hospitalized patients with CLD.

Methods

Study design and participants

This is a multicenter retrospective cohort study of patients with SARS-CoV2 infection, aged ≥18 years, who were hospitalized between March and September 2020 in Spain and included in the SEMI-COVID-19 Network.3 The registry is an initiative of the Spanish Society of Internal Medicine (SEMI, for its initials in Spanish), which included 17,416 cases by September 2020, and its characteristics have been described elsewhere.3,12 Data are collected retrospectively and include epidemiological and clinical characteristics, such as comorbidities, symptoms, physical examination findings, laboratory and diagnostic imaging test results, and clinical outcomes. STROBE Statement Guidelines were followed in the study’s design and reporting.

Definitions and data source

COVID-19 was defined as compatible symptoms and a positive result on either polymerase chain reaction (PCR) of a nasopharyngeal sample or serology test for SARS-CoV-2. Chronic lung disease (CLD) was defined as an antecedent of COPD or asthma diagnosticated by pulmonary function tests or clinical criteria of chronic bronchitis. Clinical criteria of chronic bronchitis is clinically characterized by a persistent cough lasting at least three months over two or more consecutive years.22 These changes significantly impair lung compliance and pulmonary function.23,24 Chronic bronchitis is associated with a diminished quality of life, a more rapid decline in lung function, increased frequency of exacerbations, and a higher risk of mortality, as highlighted in research by Kim et al. in 2016 and 202.25,26 Pulmonary function tests are used in the evaluation, classification and grading of a variety of forms of lung diseases with the performance of basic spirometry with or without other additional tests such as spirometry before and after a bronchodilator, lung volumes and quantification of carbon monoxide diffusing capacity. Chronic ICS use was retrieved from electronic medical records. Patients with a long-term prescription written in the past 12 months were included. Fever was considered as an axillary temperature of 38ºC or more.3

Outcome measures

The primary outcome of this study was in-hospital mortality. Secondary outcomes were the development of moderate-severe Acute Respiratory Distress Syndrome (ARDS) according to the Berlin 2012 criteria,27 transfer to an ICU, requirement of invasive mechanical ventilation, and length of stay (LOS).

The increase of inflammatory parameters (c-reactive protein, ferritin, interleukin 6, D-Dimer, lymphocyte, lactate dehydrogenase and fibrinogen) were also analyzed, comparing their values at admission and on day +7 of hospitalization and comparing the difference of medians.

Statistical analysis

Continuous variables were expressed by mean, standard deviation (SD) or median, and interquartile range (IQR). Categorical variables were summarized in terms of frequencies and percentages. Differences between groups were determined using the chi-square test or Fisher’s exact test for categorical variables; the Mann-Whitney U test, Student’s t-test or analysis of variance were used for continuous variables, as appropriate. P values <0.05 were considered statistically significant. Cases with missing data were excluded from the analysis. The SPSS statistical package version 22.0 (SPSS, Chicago, IL) was used.

Ethical aspects

Scientific and ethical permission to conduct this study was obtained from the Provincial Research Ethics Committee of Málaga (Spain). Personal data were processed in strict compliance with Spanish Law 14/2007 on Biomedical Research; Regulation (EU) 2016/679 of the European Parliament and of the Council of April 2016 on the protection of natural persons concerning the processing of personal data and on the free movement of such data (General Data Protection Regulation); and Spanish Organic Law 3/2018 on Personal Data Protection and the Guarantee of Digital Rights.

Results

Of the 17,416 patients included in the SEMI-COVID Network by September 2020, 2,598 patients had CLD, of which 1,171 patients had a diagnosis of asthma and 1,427 of COPD (see Figure 1). The mean age was 76.7 years (IQR 69.7-83.9) in COPD patients and 65.6 years (IQR 52.6-76.8) in patients with asthma. Both asthma patients with ICS and COPD patients with ICS had a significantly higher mean age [(asthma patients: 66.6 years vs. 63.4 years, p < 0.001), (COPD patients: 77.5 years vs. 76.6 years, p = 0.009)]. 79.1% of COPD patients were male, and 40.2% of asthma patients were male. Most of the patients (66.8% asthma patients and 94.5% COPD patients) had an adjusted Charlson Comorbidity Index of 3 or more points, being more frequent in those with ICS [(72.2% vs. 60.6%, p < 0.001 in asthma patients); (96.1% vs. 93.3%, p = 0.025 in COPD patients)]. The most frequent comorbidities in asthma patients were hypertension (47.4%), diabetes (15%) and heart failure (6.7%). In comparison, the most frequent comorbidities in COPD patients were hypertension (67.6%), cancer (31.6%) and diabetes (28.2%). In COPD patients, the severity of the condition was assessed with FEV1. As may be expected, patients with ICS had a more severe COPD. Other epidemiological characteristics of the patients may be seen in Table 1.

229814 Figure 1. Flowchart of patients with COVID-19 included in the SEMI-COVID Network with chronic lung disease.

229815 Table 1. Epidemiological characteristics of patients diagnosed with COVID-19 with asthma and chronic obstructive pulmonary disease according to chronic treatment with or without inhaled corticosteroids.

	Asthma	COPD	
	Total (n = 1171)	With ICS (n = 625)	Without ICS (n = 546)	p	Total (n = 1427)	With ICS (n = 591)	Without ICS (n = 836)	p	
Age (years, Median [IQR])	65.6 [52.6-76.8]	66.6 [56.8-77.3]	63.4 [47.3-76.3]	<0.001	76.7 [69.7-83.9]	77.5 [70.2-84.4]	76.6 [70.4-83.1]	0.009	
Sex (male), n (%)	471 (40.2)	252 (40.3)	219 (40.1)	0.952	1128 (79.1)	469 (79.4)	659 (78.8)	0.895	
Active smokers, n (%)	56 (4.8)	30 (4.8)	26 (4.8)	0.958	196 (13.7)	71 (12)	125 (14.9)	0.118	
Former smokers, n (%)	261 (22.3)	162 (25.9)	99 (18.1)	0.001	888 (62.2)	392 (66.3)	496 (59.3)	0.009	
Moderate-severe dependence, n (%)	123 (10.5)	57 (9.1)	66 (12.1)	0.145	333 (23.3)	137 (23.2)	196 (23.4)	0.222	
Charlson ≥3, n (%)	782 (66.8)	451 (72.2)	331 (60.6)	<0.001	1348 (94.5)	568 (96.1)	780 (93.3)	0.025	
FEV1, mean (SD)	-	-	-	-	58.6 (17.9)	57.5 (17.8)	61.6 (17.9)	0.008	
Hypertension, n (%)	555 (47.4)	317 (50.7)	238 (43.6)	0.014	964 (67.6)	414 (70.1)	550 (65.8)	0.079	
Diabetes mellitus type 2, n (%)	176 (15)	90 (14.4)	86 (15.8)	0.566	403 (28.2)	176 (29.8)	227 (86.4)	0.283	
Heart failure, n (%)	78 (6.7)	44 (7.1)	34 (6.2)	0.639	244 (17.1)	107 (18.1)	137 (16.4)	0.393	
Stroke, n (%)	14 (1.2)	3 (0.5)	11 (2)	0.027	51 (1.1)	15 (2.5)	36 (4.3)	0.078	
Moderate-severe chronic kidney disease, n (%)	48 (4.1)	26 (4.2)	22 (4)	0.910	168 (11.8)	67 (11.3)	101 (12.1)	0.739	
Cancer, n (%)	49 (4.2)	24 (3.8)	25 (4.6)	0.561	154 (31.6)	65 (11)	89 (10.6)	0.863	
Dementia, n (%)	63 (5.4)	28 (4.5)	35 (6.4)	0.155	162 (18.3)	64 (10.8)	98 (11.7)	0.612	
qSOFA	83 (7.1)	40 (6.4)	43 (7.9)	0.306	221 (15.5)	89 (15.1)	132 (15.8)	0.656	
CURB65	395 (33.7)	223 (35.7)	172 (31.5)	0.190	952 (66.7)	417 (70.6)	535 (64)	0.030	
PSI IV-V	96 (8.2)	44 (7)	52 (9.5)	0.110	323 (22.6)	139 (23.5)	184 (22)	0.745	
COPD, Chronic Obstructive Pulmonary Disease; ICS, inhaled corticosteroids; IQR, interquartile range; FEV1, Forced Expiratory Volume in the 1st second; SD, standard deviation; qSOFA, Quick Sequential Organ Failure Assessment; CURB65, Confusion, Uremia, Respiratory rate, Blood pressure, age ≥ 65; PSI IV-V, Pneumonia Severity Index.

The most frequent symptoms in chronic respiratory patients triggered by the COVID-19 infection were dyspnea (70.9% and 71.3% in asthma and COPD patients, respectively), fever (62.4% in asthma patients and 52.9% in COPD patients) and dry cough (59.9% in asthma patients and 48.5% in COPD patients). Dry cough was significantly more frequent in patients without ICS [(59.4% vs. 60.6%, p = 0.001 in asthma patients), (45.2% vs. 50.8%, p = 0.006 in COPD patients)]. In comparison, productive cough was significantly more frequent in patients with ICS [(23.1% vs. 15.6%, p < 0.001 in asthma patients), (29.6% vs. 22.2%, p = 0.006 in COPD patients)]. Dyspnea was more frequent in patients with ICS, being statistically significant in COPD patients (76.1% vs. 67.9%, p = 0.001). At lung auscultation, wheezing and roncus were more frequent in both asthma and COPD patients with ICS. Other clinical data are shown in Table 2.

229816 Table 2. Clinical characteristics of patients diagnosed with COVID-19 with asthma and chronic obstructive pulmonary disease according to chronic treatment with or without inhaled corticosteroids.

	Asthma	COPD	
	Total (n = 1171)	With ICS (n = 625)	Without ICS (n = 546)	p	Total (n = 1427)	With ICS (n = 591)	Without ICS (n = 836)	p	
Dry cough, n (%)	702 (59.9)	371 (59.4)	331 (60.6)	0.001	692 (48.5)	267 (45.2)	425 (50.8)	0.006	
Productive cough, n (%)	229 (19.6)	144 (23.1)	85 (15.6)	<0.001	361 (25.3)	175 (29.6)	186 (22.2)	0.016	
Arthromyalgia, n (%)	384 (32.8)	206 (33)	178 (32.6)	0.851	314 (22)	127 (21.5)	187 (22.4)	0.746	
Ageusia, n (%)	109 (9.3)	50 (8)	59 (10.8)	0.158	56 (3.9)	18 (3)	38 (4.5)	0.168	
Anosmia, n (%)	79 (6.7)	36 (5.8)	43 (7.9)	0.200	53 (3.7)	18 (3)	35 (4.2)	0.320	
Asthenia, n (%)	528 (45.1)	279 (44.6)	249 (45.6)	0.991	586 (41.1)	252 (42.6)	334 (40)	0.297	
Anorexy, n (%)	192 (16.4)	105 (16.8)	87 (15.9)	0.635	263 (18.4)	104 (17.6)	159 (19)	0.578	
Pharyngodynia, n (%)	114 (9.7)	59 (9.4)	55 (10.1)	0.844	119 (8.3)	51 (8.6)	68 (8.1)	0.770	
Headache, n (%)	165 (14.1)	95 (15.2)	70 (12.8)	0.207	93 (6.5)	34 (5.8)	59 (7)	0.330	
Febricula (Tª 37.5-38ºC), n (%)	251 (21.4)	140 (22.4)	111 (20.3)	0.414	332 (23.3)	153 (25.9)	179 (21.4)	0.250	
Fever (Tª > 38ºC), n (%)	731 (62.4)	389 (62.2)	342 (62.6)	0.988	755 (52.9)	305 (51.6)	450 (53.8)	0.120	
Dyspnea, n (%)	830 (70.9)	458 (73.3)	372 (68.1)	0.061	1018 (71.3)	450 (76.1)	568 (67.9)	0.001	
Confusion, n (%)	89 (7.6)	42 (6.7)	47 (8.6)	0.226	243 (17)	100 (16.9)	143 (17.1)	0.886	
Tachypnea (>20 bpm), n (%)	372 (31.8)	195 (31.2)	177 (32.4)	0.613	659 (46.2)	279 (47.2)	380 (45.5)	0.703	
Crackles, n (%)	564 (48.2)	301 (48.2)	263 (48.2)	0.972	779 (54.6)	313 (52.9)	466 (55.7)	0.380	
Wheezing, n (%)	221 (18.9)	139 (22.2)	82 (15)	0.002	212 (14.9)	117 (19.8)	95 (11.4)	<0.001	
Roncus, n (%)	160 (13.7)	103 (16.5)	57 (10.4)	0.003	354 (24.8)	174 (29.4)	180 (21.5)	0.001	
COPD, Chronic Obstructive Pulmonary Disease; ICS, inhaled corticosteroids; bpm, breaths per minute; Tª, temperature.

Regarding the inflammatory parameters (Table 3), there was a significant decrease in CRP and IL6 in all groups, except in COPD patients with ICS, where the decrease was not statistically significant (p = 0.087). Ferritin increased in all groups but was statistically significant only in COPD patients (with ICS p = 0.001, without ICS p = 0.003). D-dimer also increased in all groups but was not statistically significant in COPD patients with ICS (p = 0.062). Lymphocytes increased in asthma patients (statistically significant in asthma patients with ICS, p = 0.041) and decreased in COPD patients (statistically significant in COPD patients without ICS, p = 0.045).

229817 Table 3. Variation of inflammatory parameters in patients with asthma and chronic obstructive pulmonary disease admitted to hospital due to COVID-19 according to chronic treatment with or without inhaled corticosteroids.

			At admission	At 7 days control	p	
Asthma	With ICS	CRP	54 [19-128]	21 [6-68]	<0.001	
Ferritin	462 [200-930]	531 [243-1004]	0.065	
IL-6	26.1 [9.7-62.9]	16 [4.2-60]	0.003	
D-dimer	620 [336-940]	666 [356-1206]	<0.001	
Lymphocytes	990 [700-1300]	1120 [720-1580]	0.041	
Without ICS	CRP	52 [16-113]	20 [5-57]	<0.001	
Ferritin	475 [186-899]	538 [228-948]	0.066	
IL-6	24.8 [5.5-59.9]	10.2 [2.1-35]	<0.001	
D-dimer	520 [289-1085]	598 [338-1254]	0.016	
Lymphocytes	1030 [770-1400]	1200 [800-1700]	0.083	
COPD	With ICS	CRP	78 [26-152]	40 [10-128]	<0.001	
Ferritin	547 [248-1047]	691 [350-1178]	0.001	
IL-6	24.1 [11.4-52]	16.5 [5.1-45.4]	0.087	
D-dimer	818 [408-1375]	831 [434-1625]	0.062	
Lymphocytes	890 [590-1200]	840 [542-1037]	0.085	
Without ICS	CRP	76 [23-147]	35 [11-118]	<0.001	
Ferritin	493 [256-979]	611 [287-1283]	0.003	
IL-6	32.1 [15.1-86.6]	24.5 [9.6-81]	0.031	
D-dimer	835 [480-1434]	900 [461-1913]	0.001	
Lymphocytes	820 [560-1220]	733 [533-1000]	0.045	
COPD, Chronic Obstructive Pulmonary Disease; ICS, inhaled corticosteroids; CRP, c-reactive protein; IL-6, Interleukin 6.

Patients with chronic ICS had a longer hospital stay in asthma and COPD patients (9 vs. 8 days, p = 0.031 in asthma patients), (11 vs. 9 days, p = 0.018 in COPD patients). No differences were found in-hospital mortality, transfer to ICU, or the development of moderate-severe ARDS (Table 4).

229818 Table 4. Prognostic factors of patients with a history of asthma and COPD diagnosed with COVID-19 according to chronic treatment with or without inhaled corticosteroids

	Asthma	COPD	
	Total
(n = 1171)	With ICS
(n = 625)	Without ICS (n = 546)	p	Total
(n = 1427)	With ICS
(n = 591)	Without ICS (n = 836)	p	
In-hospital mortality, n (%)	166 (14.2)	87 (13.9)	79 (14.5)	0.802	525 (36.8)	233 (39.4)	292 (34.9)	0.084	
Moderate-severe ARDS, n (%)	260 (22.2)	137 (21.9)	123 (22.5)	0.778	526 (36.9)	233 (39.4)	293 (35)	0.106	
Sepsis, n (%)	60 (5.1)	32 (5.1)	28 (5.1)	0.983	117 (8.2)	50 (8.5)	67 (8)	0.770	
Pulmonary thromboembolism, n (%)	22 (1.9)	13 (2.1)	9 (1.6)	0.744	21 (1.5)	6 (1)	15 (1.8)	0.324	
Transfer to ICU, n (%)	126 (10.8)	63 (10.1)	63 (11.5)	0.450	102 (7.1)	38 (6.4)	64 (7.7)	0.405	
Invasive mechanical ventilation, n (%)	100 (8.5)	52 (8.3)	48 (8.8)	0.754	79 (5.5)	30 (5.1)	49 (5.9)	0.558	
Non-invasive mechanical ventilation, n (%)	66 (5.6)	34 (5.4)	32 (5.9)	0.800	135 (9.5)	70 (11.8)	65 (7.8)	0.013	
Hospital stay (days), Median [IQR]	9 [5-13]	9 [6-14]	8 [5-12]	0.031	9 [5-16]	11 [6-17]	9 [5-15]	0.018	
COPD, Chronic Obstructive Pulmonary Disease; ICS, inhaled corticosteroids; ARDS, Acute Respiratory Distress Syndrome; ICU, Intensive Care Unit; IQR, interquartile range.

Discussion

In our study, we aimed to investigate the influence of chronic treatment with ICS on the prognosis of COVID-19 hospitalized patients with CLD. We found that patients with COVID-19 and chronic ICS did have more dyspnea and productive cough at admission, as well as a longer hospital stay. Chronic treatment with ICS in patients with asthma and COPD did not influence in-hospital mortality or other prognostic factors such as transfer to ICU, development of moderate-severe ARDS or requirement of invasive mechanical ventilation.

At the beginning of the SARS-CoV-2 pandemic, it was suggested that patients with CLD could have a worse prognosis.11 Influence of chronic ICS was controversial since its use is a known risk factor for pneumonia,28,29 but it was also suggested that it may improve prognosis due to its inhibition of viral replication.19 The STOIC and PRINCIPLE trials published later showed that inhaled budesonide in outpatients reduced time to recovery after early COVID-19, and a recently published clinical trial suggests that using inhaled budesonide may reduce the risk of worsening in hospitalized patients with COVID-19 pneumonia.30,31

In our results, patients treated with chronic corticosteroid therapy (both asthma and COPD) had a higher mean age and more comorbidities, just as was inferred in other articles, compared to patients without ICS. Patients with CLD treated with chronic ICS did not have more severe disease at admission, according to qSOFA and CURB-65, despite having more comorbidities (Charlson ≥3 83.8%). In addition, the severity of COPD (assessed with FEV1) was associated with an increased use of inhaled corticosteroids, as expected.32,33

Asthma and COPD patients treated with chronic ICS did not have higher in-hospital mortality, coinciding with other studies,17,29,34 nor had higher rates of moderate-severe ARDS, transfer to ICU or requirement of invasive mechanical ventilation. Similar results were found by Sen P. et al. in patients with COPD who tested positive for COVID-19.35 However, both asthma and COPD patients treated with ICS had a longer hospital stay. The fact that these patients had a longer hospital stay could be due to factors such as older age and comorbidity measured with the Charlson comorbidity index.

In our study, patients with CLD treated with chronic ICS had a more frequently productive cough, as suggested by Hasan et al. in a study that associates ICS with the risk of respiratory infection.28

It has been suggested that chronic ICS may reduce the inflammation produced by SARS-CoV-2.17,19,21 We analyzed the evolution of inflammatory parameters of these patients during admission and observed that chronic ICS did not have an influence. To our knowledge, this is the first multicenter study that evaluates the evolution of these parameters, which have been related to poor prognosis in COVID-19,36 in patients with chronic ICS.

The main strength of this study is its multicenter, nationwide design and the large number of patients included. The main limitation is that only inpatients were included; therefore, the results may be different for outpatients. Another important limitation is that the different types of ICS were not analyzed separately, so their different degrees of systemic effects could influence the results. Because of the study’s retrospective design, some patients had incomplete information regarding their use of inhaled corticosteroids; these patients were not included, as described in the flow chart (Figure 1). It should be taken into account that the study was developed during the first and second waves of COVID-19 in Spain with different strains of SARS-CoV-2 than from those currently existing and without any vaccination.

The outcomes of this study support the maintenance of ICS in patients admitted for COVID-19. Despite its limitations, its results are very useful in clinical practice since the patients in this study have epidemiological characteristics similar to those in subsequent pandemic waves.37

Conclusions

Patients with chronic inhaled corticosteroids had longer hospital stay and more chronic comorbidities, measured by the Charlson comorbidity index, but they did not have more severe disease at admission, evaluated with qSOFA and PSI scores. Chronic treatment with ICS had no influence on the prognosis of patients with chronic lung disease and COVID-19.

Ethical Approval

Scientific and ethical permission to conduct this study was obtained from the Provincial Research Ethics Committee of Málaga (Spain).

Competing Interests

All authors have completed the ICMJE uniform disclosure form and declare no conflict of interest.

AI statement

The authors confirm no generative AI or AI-assisted technology was used to generate content.

Acknowledgments

We gratefully acknowledge all the investigators who participated in the SEMI-COVID-19 Registry.
==== Refs
Intensive care during the coronavirus epidemic Intensive Care Med Qiu H. Tong Z. Ma P. Hu M. Peng Z. Wu W.. 2020
46 4 576 8 10.1007/s00134-020-05966-y 10.1007/s00134-020-05966-y 32077996
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention JAMA Wu Z. McGoogan J. M. 2020
323 13 1239 1242 10.1001/jama.2020.2648 10.1001/jama.2020.2648
Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19 Rev Clin Esp (Barc) Casas-Rojo J. M. Antón-Santos J. M. Millán-Núñez-Cortés J.. 2020
220 8 480 494 32762922
Clinical course and mortality risk of severe COVID-19 Lancet Weiss P. Murdoch D. R. 2020
395 10229 1014 1015 10.1016/S0140-6736(20)30633-4 10.1016/S0140-6736(20)30633-4 32197108
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020 Apr;8(4):e26] Lancet Respir Med Yang X. Yu Y. Xu J. 2020
8 5 475 481 10.1016/S2213-2600(20)30079-5 10.1016/S2213-2600(20)30079-5 32105632
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med Halpin D.M.G. Faner R. Sibila O. Badia J.R. Agusti A. 2020
8 5 436 438 10.1016/S2213-2600(20)30167-3 10.1016/S2213-2600(20)30167-3 32251625
COVID-19 et asthme [COVID-19 and asthma] Louis R. Calmes D. Frix A. N. Schleich F. 2020
75 S1 130 132
Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med Lippi G. Henry B.M. 2020
167 105941 10.1016/j.rmed.2020.105941 10.1016/j.rmed.2020.105941
COPD at the Time of COVID-19: A COPD Foundation Perspective Chronic Obstr Pulm Dis Tal-Singer R. Crapo J. D. 2020
7 2 73 75 10.15326/jcopdf.7.2.2020.0149 10.15326/jcopdf.7.2.2020.0149 32324976
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Eur Respir J Guan W. J. Liang W. H. Zhao Y. 14 5 2020
55 5 2000547 10.1183/13993003.00547-2020
The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis J Med Virol Zhao Q. Meng M. Kumar R. 2020
92 10 1915 1921 10.1002/jmv.25889 10.1002/jmv.25889 32293753
Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2 Int J Chron Obstruct Pulmon Dis Gómez Antúnez M. Muiño Míguez A. Bendala Estrada A.D.. 2021
15 3433 3445 10.2147/COPD.S276692 10.2147/COPD.S276692 33447021
Inhaled corticosteroids in virus pandemics: a treatment for COVID-19? Lancet Respir Med Nicolau D. V. Bafadhel M. 2020
8 9 846 847 10.1016/S2213-2600(20)30314-3 10.1016/S2213-2600(20)30314-3 32738928
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] Lancet Zhou F. Yu T. Du R.. 2020
395 10229 1054 1062 32171076
Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges Respir Med Res Deslée G. Zysman M. Burgel P. R. 2020
78 100764 10.1016/j.resmer.2020.100764 10.1016/j.resmer.2020.100764 32498023
Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids? Expert Rev Respir Med Rogliani P. Lauro D. Di Daniele N. Chetta A. Calzetta L. 2021
15 4 561 568 10.1080/17476348.2021.1850275 33183113
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective Eur Respir J Halpin D. M. G. Singh D. Hadfield R. M. 7 5 2020
55 5 2001009 10.1183/13993003.01009-2020 10.1183/13993003.01009-2020 32341100
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells Respir Investig Yamaya M. Nishimura H. Deng X. 2020
58 3 155 168 10.1016/j.resinv.2019.12.005 10.1016/j.resinv.2019.12.005
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells J Virol Matsuyama S. Kawase M. Nao N. 9 12 2020
95 1 e01648 20 10.1128/JVI.01648-20 10.1128/JVI.01648-20
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon J Allergy Clin Immunol Finney L. J. Glanville N. Farne H. 2021
147 2 510 519.e5 10.1016/j.jaci.2020.09.034 10.1016/j.jaci.2020.09.034 33068560
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis [published correction appears in Lancet Respir Med. 2022 Jun;10(6):e60] Lancet Respir Med Baker J. R. Mahdi M. Nicolau D. V., Jr.. 2022
10 6 545 556 35397798
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024-3-14 http://www.goldcopd.org
Delay of airway epithelial wound repair in COPD is associated with airflow obstruction severity Respir Res Perotin J. M. Adam D. Vella-Boucaud J.. 27 11 2014
15 1 151 10.1186/s12931-014-0151-9 10.1186/s12931-014-0151-9
Correlation between sestrin2 expression and airway remodeling in COPD BMC Pulm Med Zhang D.W. Wei Y.Y. Ji S. Fei G.H. 16 11 2020
20 1 297 10.1186/s12890-020-01329-x 10.1186/s12890-020-01329-x
Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease Ann Am Thorac Soc Kim V. Zhao H. Boriek A.M.. 2016
13 7 1016 1025 10.1513/AnnalsATS.201512-800OC 10.1513/AnnalsATS.201512-800OC 27158740
Clinical Impact of the Bronchiectasis with Chronic Bronchitis Symptoms in COPD: Analysis of a Longitudinal Cohort Int J Chron Obstruct Pulmon Dis Kim E. K. Kim M. A. Lee J. S.. 1 11 2021
16 2997 3008 10.2147/COPD.S332299 10.2147/COPD.S332299
Acute respiratory distress syndrome: the Berlin Definition JAMA ARDS Definition Task Force Ranieri V. M. Rubenfeld G. D.. 2012
307 23 2526 2533 10.1001/jama.2012.5669 10.1001/jama.2012.5669 22797452
Use of corticosteroids in asthma and COPD patients with or without COVID-19 Respir Med Hasan S.S. Capstick T. Zaidi S.T.R. Kow C.S. Merchant H.A. 2020
170 106045 10.1016/j.rmed.2020.106045 10.1016/j.rmed.2020.106045 32843175
Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? Lancet Respir Med Singh D. Halpin D.M.G. 2020
8 11 1065 1066 10.1016/S2213-2600(20)30447-1 10.1016/S2213-2600(20)30447-1 32979985
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial [published correction appears in Lancet Respir Med. 2021 Jun;9(6):e55] Lancet Respir Med Ramakrishnan S. Nicolau D. V., Jr. Langford B.. 2021
9 7 763 772 10.1016/S2213-2600(21)00160-0 10.1016/S2213-2600(21)00160-0 33844996
Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial Eur Respir J Agustí A. De Stefano G. Levi A. 10 3 2022
59 3 2103036 10.1183/13993003.03036-2021 10.1183/13993003.03036-2021
Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review Respir Res Whittaker H. R. Jarvis D. Sheikh M. R. Kiddle S. J. Quint J. K. 4 12 2019
20 1 277 10.1186/s12931-019-1249-x 10.1186/s12931-019-1249-x
Risk Factors for Development and Severity of COVID-19 in COPD Patients Front Med (Lausanne) Bonato M. Semenzato U. Tinè M.. 9 8 2021
8 714570 10.3389/fmed.2021.714570 10.3389/fmed.2021.714570 34434947
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform Lancet Respir Med Schultze A. Walker A. J. MacKenna B.. 2020
8 11 1106 1120 10.1016/S2213-2600(20)30415-X 10.1016/S2213-2600(20)30415-X 32979987
Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry PLoS One Sen P. Majumdar U. Zein J. Hatipoğlu U. Attaway A.H. 3 6 2021
16 6 e0252576 10.1371/journal.pone.0252576 10.1371/journal.pone.0252576 34081722
The role of biomarkers in diagnosis of COVID-19 - A systematic review Life Sci Kermali M. Khalsa R.K. Pillai K. Ismail Z. Harky A. 2020
254 117788 10.1016/j.lfs.2020.117788 10.1016/j.lfs.2020.117788 32475810
Hospitalization burden and epidemiology of the COVID-19 pandemic in Spain (2020-2021) BMC Infect Dis Garcia-Carretero R. Vazquez-Gomez O. Gil-Prieto R. Gil-de-Miguel A. 18 7 2023
23 1 476 10.1186/s12879-023-08454-y 10.1186/s12879-023-08454-y
